Home Impact of Nautilus on Biotech and Pharmaceutical Patents
 

Keywords :   


Impact of Nautilus on Biotech and Pharmaceutical Patents

2015-11-16 21:13:08| Biotech - Topix.net

In Nautilus, Inc. v. Biosig Instruments, Inc. , 134 S. Ct. 2120 , the Supreme Court rejected the Federal Circuit's "insolubly ambiguous" standard for determining whether a patent claim meets the definiteness requirement under 35 U.S.C. 112, 2, and held that "a patent is invalid for indefiniteness if its claims, read in light of the specification delineating the patent, and the prosecution history, fail to inform, with reasonable certainty, those skilled in the art about the scope of the invention."

Tags: impact patents pharmaceutical biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06VW to invest up to $5bn in Tesla rival Rivian
26.06Strategic use of soybean meal to maximize hog carcass weight during summer
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06Aer Lingus pilots begin industrial action over pay dispute
25.06Water requirements in the summer
More »